Last reviewed · How we verify
Ketorolac 0.5% Eye Drops
Ketorolac 0.5% Eye Drops, marketed by St. Joseph's Healthcare Hamilton, is a non-steroidal anti-inflammatory drug (NSAID) used for ocular pain management. The key composition patent expires in 2028, providing a strong barrier to generic competition until then. The primary risk is the lack of revenue data, which makes it challenging to assess the drug's market performance and potential threats from competitors.
At a glance
| Generic name | Ketorolac 0.5% Eye Drops |
|---|---|
| Also known as | Acular, Acular LS, Acuvail |
| Sponsor | St. Joseph's Healthcare Hamilton |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population (PHASE4)
- Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC (PHASE1, PHASE2)
- Assessment of the Effects and Tolerability of RD03/2016 for the Treatment of Bacterial Conjunctivitis in Adults (PHASE2)
- Ketorolac Levels in Vitreous and Aqueous Samples From Patients Undergoing Combined Cataract and Pars Plana Vitrectomy Surgeries With and Without Intracameral Phenylephrine 1.0% / Ketorolac 0.3% (EARLY_PHASE1)
- Efficacy of NSAID vs. Steroid-NSAID Combo Post-Selective Laser Trabeculoplasty: Phase 4, Single-Center RCT (PHASE4)
- A Trial Evaluating Patient Preference of Dropless vs Drops Post Cataract Surgery (PHASE4)
- Steroids After Laser Trabeculoplasty for Glaucoma (PHASE4)
- Nepafenac Versus Ketorolac Eye Drops in Prevention of Intraoperative Miosis During Cataract Surgery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketorolac 0.5% Eye Drops CI brief — competitive landscape report
- Ketorolac 0.5% Eye Drops updates RSS · CI watch RSS
- St. Joseph's Healthcare Hamilton portfolio CI